Q2 FY2026 EarningsQ2 FY26 results beat consensus on top and bottom lines: revenue $104K vs. $62.8K expected, and GAAP EPS -$0.14 vs. -$0.16 expected. Net loss of $9.2M was narrower than the $11.9M consensus, driven primarily by a $5.7M YoY reduction in R&D expenses due to clinical trial completions. Despite the beat, the company issued a 'going concern' warning, noting cash reserves of $34.5M are insufficient for the next 12 months, though a subsequent $10.1M offering in July extends the runway into Q3 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cardiff Oncology(CRDF) the Revenue is 104 K (-14.05%), Beat estimate;the EBIT is -9.615 M (+34.93%), Beat estimate;the EPS is -0.14 (+33.33%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B14.05%
0.00B48.12%
+0.00B34.07%
EBITExceed expectations
-0.01B34.93%
-0.01B17.59%
+0.00B17.34%
EPSExceed expectations
-0.1433.33%
-0.1623.81%
+0.02009.52%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf